EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM

Overview of innovation in Hodgkin's lymphoma

EHA 2015: Expert opinions on new treatment standard in multiple myeloma

Genomic sequencing to find AML-causing mutations

The latest in multiple myeloma: a European and US perspective

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia

Transplantation combined with novel agents optimal treatment for multiple myeloma

Monoclonal antibodies and multiple myeloma

Factors influencing response to blinatumomab in relapsed/refractory ALL

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma